OakChart

Microbot Medical Inc

MBOTHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 1:41 PM ET

1.11+0.06 (5.24%)
2026-11-11 19:42 CET
Market cap
70.52 USD m
Revenue, TTM
0.35 USD m
Net income, TTM
-16.34 USD m
Free cash flow, TTM
-17.93 USD m
EPS diluted, TTM
-0.26
P/E
-
Compare

Price

MBOT against its 20, 50 and 200-day averages
2050200earnings
1.001.502.002.504.5M8.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MBOTclose 1.1120-day 1.0350-day 1.18200-day 1.811.1152w low

61.3% under the 52-week high of 2.86 on 11 Mar 2026. 52-week low 0.93 on 15 Oct 2026. Last 15 sessions, 26.9% high to low

Profile

MBOT
52-week range, 9% of the way up
0.932.86

Microbot Medical, Inc. is a medical device company, which engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Employees43
IPOMar 25, 1992
Beta1.03
ATR, 14d0.07
Rel volume1.12
Short float10.36%
Insider own9.14%
Inst own17.44%

Snapshot

6 groups

Valuation

Index-
Market Cap74.21M
Enterprise Value6.71M
Income-16.34M
Sales0.35M
Book/sh1.03
Cash/sh1.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees43
IPOMar 25, 1992

Ratios

P/E-
Forward P/E-
PEG-
P/S212.04
P/B1.08
P/C1.09
P/FCF-
EV/EBITDA-
EV/Sales19.18
Quick Ratio17.82
Current Ratio18.56
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.26
EPS next Y-0.32
EPS next Q-0.08
EPS this Y-5.17%
EPS next Y-4.92%
EPS next 5Y8.80%
EPS past 3/5Y45.91% 25.94%
Sales past 3/5Y- -
EPS Y/Y TTM53.95%
Sales Y/Y TTM-
EPS Q/Q12.62%
Sales Q/Q-
EarningsAug 18
EPS/Sales Surpr.-8.84% 0.00%

Ownership

Insider Own9.14%
Insider Trans0.00%
Inst Own17.44%
Inst Trans-19.56%
ROA-30.68%
ROE-32.91%
ROIC-23.52%
Gross Margin-198.84%
Oper. Margin-5348.84%
Profit Margin-4722.25%
SMA206.95%
SMA50-6.54%
SMA200-38.93%
Trades-

Technical

Shs Outstand67.16M
Shs Float61.03M
Short Float10.36%
Short Ratio8.23
Short Interest6.32M
52W High2.86 -61.30%
52W Low0.93 18.82%
Volatility7.42% 6.63%
ATR (14)0.07
RSI (14)50.94
Beta1.03
Rel Volume1.12
Avg Volume768.54K
Volume572,455

Performance

Perf Week-3.07%
Perf Month8.33%
Perf Quarter-34.23%
Perf Half Y-49.08%
Perf YTD-44.75%
Perf Year-47.13%
Perf 3Y-18.75%
Perf 5Y-84.15%
Perf 10Y-99.26%
Recom1.00
Target Price5.38
Prev Close1.05
Price1.11
Change %5.24%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Oct 23, 2026InitiatedCCitizensMkt Outperform$2.50+126.2%
Sep 11, 2026ResumedRB. Riley SecuritiesBuy$4+262.0%
Feb 10, 2026InitiatedRB. Riley SecuritiesBuy$5+352.5%
Dec 03, 2025InitiatedRRoth CapitalBuy$5.50+397.7%
Jan 13, 2020ReiteratedHH.C. WainwrightBuy$12 → $26+2,252.9%
Dec 24, 2019ReiteratedHH.C. WainwrightBuy$10 → $12+986.0%
Jan 31, 2018InitiatedLLadenburg ThalmannBuy$1.75+58.4%

Peers

Mkt cap
TickerCompanyMkt cap
STXSStereotaxis Inc88.21M
SSIISS Innovations International Inc308.74M
PENPenumbra Inc12.68B
PRCTProcept BioRobotics Corp1.33B
MYOMyomo Inc52.13M
AORTArtivion Inc993.36M
ARAYAccuray Inc9.99M
MDTMedtronic Plc129.35B
ISRGIntuitive Surgical Inc154.45B
LMATLemaitre Vascular Inc1.80B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M

News

latest 14 of 200
  • Microbot Medical Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion (GlobeNewswire) -6.14%
  • Microbot Medical Secures its First Office-Based Lab (OBL) Customer for the LIBERTY Endovascular Robotic System (GlobeNewswire) +9.38%
  • Microbot Medical Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S. (GlobeNewswire)
  • Microbot Medical Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio (GlobeNewswire)
  • Microbot Medical and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel (GlobeNewswire)
  • Microbot Medical Highlights Growth Strategy (GlobeNewswire)
  • Microbot Medical Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter (GlobeNewswire) -13.18%
  • Microbot Medical Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting (GlobeNewswire)
  • Microbot Medical Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026 (GlobeNewswire)
  • Microbot Medical Increases Manufacturing Capacity as Demand for the LIBERTY System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader (GlobeNewswire)
  • Microbot Medical Wins Surgical Robotics Industry Award for the LIBERTY Endovascular Robotic System (GlobeNewswire)
  • Microbot Medical Announces First Health System in Pennsylvania to Adopt the LIBERTY Endovascular Robotic System (GlobeNewswire)
  • Microbot Medical Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations (GlobeNewswire)
  • Microbot Medical Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY Endovascular Robotic System (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-18-0.081-0.075-0.0800.130.133
2026Q12026-05-12-0.050-0.080-0.0550.070.452
2025Q42026-02-25-0.050-0.060-0.0520.000.113
2025Q32025-11-07-0.070-0.060-0.0740.000.601
2025Q22025-08-12-0.100-0.080-0.0960.000.001
2025Q12025-05-13-0.080-0.130-0.0840.000.001
2024Q42025-02-26-0.190-0.180-0.1990.000.001
2024Q32024-11-01-0.200--0.1950.00--
2024Q22024-08-13-0.170-0.170-0.1660.000.001
2024Q12024-05-14-0.170-0.170-0.1690.00-1
2023Q42024-02-28-0.270-0.250-0.269--1
2023Q22023-08-15-0.250-0.310-0.249--1
2023Q12023-05-18-0.360-0.450-0.3560.00-1
2022Q42023-05-17-0.400-0.470-0.3830.000.001
2022Q32022-11-14-0.490-0.510-0.4880.000.001
2022Q22022-08-15-0.490-0.450-0.494--1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-2.410--2.4120.00-
2019FY-1.700-1.560-1.698--
2020FY-1.290-1.250-1.288--
2021FY-1.590-1.590-1.592--
2022FY-1.810-1.900-1.814--
2023FY-1.050--1.0530.00-
2024FY-0.730-0.710-0.7310.000.00
2025FY-0.290-0.300-0.2900.000.11
2026FY--0.305--0.36
2027FY--0.320--4.51
2028FY--0.220--19.14
2029FY--0.090--48.20

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-224030.01-0.520.30
2026Q3S2026-10-20303-0.09-0.520.25
2026Q3S2026-09-24303-0.07-0.520.30
2026Q3S2026-09-103030.26-0.521.00
2026Q3S2026-08-183030.570.301.00
2026Q3S2026-08-123030.620.401.00
2026Q3S2026-08-103020.920.451.30
2026Q3S2026-07-283010.950.451.30
2026Q3S2026-07-093110.950.451.30
2026Q3S2026-06-023101.501.102.10
2026Q3S2026-05-142101.701.302.10
2026Q3S2026-05-122001.551.012.10
2026Q3S2026-05-062001.551.012.10
2026Q3S2026-02-253101.401.012.10

Estimate history

EPS, annual-2.757-2.412-1.698-1.288-1.592-1.814-1.053-0.731-0.287-0.2644
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.166-0.195-0.199-0.084-0.096-0.074-0.052-0.055-0.084
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000.35
Period201720182019202020212022202320242025TTM
Sales, quarterly00000000.1050.241
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.7063.0127.1867.1087.1087.89111.70719.467.15867.165
Period201720182019202020212022202320242025MRQ
Shares, quarterly15.96616.65119.434.74437.95865.83467.15867.15867.165
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.350.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.030.050.090.110.100.080.070.080.05
Gross Profit-0.69-0.05-0.09-0.11-0.10-0.08-0.07-0.08-0.05
Selling, General and Administrative Excl. Other17.8214.7011.539.7513.1811.289.027.167.19
Research and Development5.826.246.545.627.636.083.332.972.49
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-18.51-14.74-11.62-9.86-13.28-11.36-9.09-7.24-7.24
Interest Expense0.000.000.000.000.000.000.080.100.02
Unusual Expense0.00-0.320.001.110.000.000.00--0.02
Net Income Before Taxes-16.34-13.14-11.44-10.74-13.17-11.31-9.17-7.25-7.26
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-16.34-13.14-11.44-10.74-13.17-11.31-9.17-7.25-7.26
Net Income From Continuing Operations-16.34-13.14-11.44-10.74-13.17-11.31-9.17-7.25-7.26
Net Income-16.34-13.14-11.44-10.74-13.17-11.31-9.17-7.25-7.01
EPS (Recurring)-0.24-0.29-0.73-0.98-1.81-1.59-1.29-1.70-2.41
EPS (Basic, Before Extraordinaries)-0.26-0.29-0.73-1.05-1.81-1.59-1.29-1.70-2.41
EPS (Diluted)-0.26-0.29-0.73-1.05-1.81-1.59-1.29-1.70-2.41
EBITDA-18.46-14.70-11.53-9.75-13.18-11.28-9.02-7.16-7.19
Non-Operating Income (Expense)2.171.280.180.230.110.040.000.100.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.221.061.351.401.751.391.941.101.40
Price To Sales Ratio378.52--------
Gross Margin-198.84--------
Operating Margin-5,348.84--------
Net Margin-4,722.25--------
Shares Outstanding67.1667.1619.4011.717.897.117.117.193.01
Market Capitalization70.5270.5218.9619.2023.7553.3148.9843.815.01

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.240.100.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.900.120.010.010.010.010.030.02
Gross Profit-0.66-0.01-0.01-0.01-0.01-0.01-0.03-0.02
Selling, General and Administrative Excl. Other5.534.314.133.853.713.013.403.28
Research and Development1.851.281.531.162.101.441.962.04
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.19-4.32-4.14-3.86-3.72-3.02-3.43-3.30
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-5.63-3.67-3.46-3.58-3.50-2.60-3.39-3.21
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.63-3.67-3.46-3.58-3.50-2.60-3.39-3.21
Net Income From Continuing Operations-5.63-3.67-3.46-3.58-3.50-2.60-3.39-3.21
Net Income-5.63-3.67-3.46-3.58-3.50-2.60-3.39-3.21
EPS (Recurring)-0.08-0.05-0.05-0.07-0.10-0.08-0.20-0.20
EPS (Basic, Before Extraordinaries)-0.08-0.05-0.05-0.07-0.10-0.08-0.20-0.20
EPS (Diluted)-0.08-0.05-0.05-0.07-0.10-0.08-0.20-0.20
EBITDA-6.17-4.31-4.13-3.85-3.71-3.01-3.40-3.28
Non-Operating Income (Expense)0.560.650.670.280.220.420.040.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.430.220.240.330.240.260.320.85
Price To Sales Ratio378.521,541.44------
Gross Margin-273.03-9.52------
Operating Margin-2,567.63-4,114.29------
Net Margin-2,334.85-3,496.19------
Shares Outstanding67.1667.1667.1665.8337.9634.7419.4016.65
Market Capitalization70.52161.85134.32138.9191.6752.4618.9614.75

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments78.595.526.438.2815.5824.7335.655.2610.81
Short Term Receivables0.240.091.330.100.170.340.100.070.04
Inventories0.580.000.000.000.000.000.000.000.00
Other Current Assets0.400.210.150.430.130.180.180.090.08
Total Current Assets79.825.827.928.8115.8825.2535.945.4210.93
Net Property, Plant & Equipment0.930.210.410.720.891.031.190.260.09
Total Investments and Advances0.060.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets0.19--------
Other Assets0.740.000.000.000.000.000.000.410.00
Total Assets81.736.038.339.5416.7726.2837.136.0911.02
Short Term Debt Incl. Current Port. of LT Debt0.300.070.190.280.280.190.140.000.00
Accounts Payable0.510.170.360.120.280.280.280.630.08
Other Current Liabilities2.612.233.241.671.430.884.404.130.45
Total Current Liabilities3.422.463.792.071.981.344.834.760.53
Long Term Debt0.570.040.040.180.400.630.760.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.19--------
Other Liabilities0.000.000.000.000.000.000.000.000.03
Total Liabilities4.182.503.832.252.391.975.594.760.56
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.50
Common Equity77.553.534.507.2914.3824.3131.541.339.96
Total Shareholders Equity77.553.534.507.2914.3824.3131.541.3310.46
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity77.553.534.507.2914.3824.3131.541.3310.46
Total Liabilities & Stockholders Equity81.736.038.339.5416.7726.2837.136.0911.02
Book Value Per Share1.150.180.380.922.023.424.390.443.68
Tangible Book Value Per Share1.150.180.380.922.023.424.390.443.68
Full-Time Employees43212221201411108
Price to Book Ratio1.024.902.613.873.712.012.323.923.36
Return on Assets-29.95-159.40-120.24-100.12-52.56-28.92-33.54-84.86-105.49
Return on Equity-32.42-284.97-182.19-121.53-58.48-32.84-44.11-123.11-124.82
Return on Invested Capital-16.82-320.44-236.51-176.33-76.53-36.77-22.44-545.86-72.52
Quick Ratio23.162.372.094.268.0018.787.451.1420.70
Current Ratio23.332.372.094.268.0018.787.451.1420.70

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-16.34-13.14-11.44-10.74-13.17-11.31-9.17-7.25-7.26
Depreciation0.050.050.090.110.100.080.070.080.05
Other Funds (Non Cash)1.121.061.352.111.751.391.870.981.47
Funds from Operations-15.17-12.04-10.00-8.52-11.32-9.85-7.23-6.18-5.73
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.47-1.011.18-0.01-0.230.50-0.02-0.270.42
Cash from Operating Activities-17.64-13.05-8.83-8.53-11.55-9.35-7.25-6.45-5.31
Capital Expenditures-0.29-0.06-0.03-0.03-0.08-0.07-0.09-0.22-0.22
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.260.00
Purchase or Sale of Investments-35.53-72.321.562.00-3.753.27-2.68-2.500.00
Purchase of Investments-52.08-82.93-5.12-10.06-3.750.00-5.20-2.500.00
Sale Or Maturity of Investments16.5510.606.6812.060.003.272.520.000.00
Other Uses-0.960.000.000.00-0.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-36.78-72.381.541.97-3.843.20-2.77-2.45-0.22
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock53.7086.247.946.564.320.00-3.3836.770.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock53.7086.247.946.564.320.00-3.3836.770.00
Proceedsfrom Stock Options53.6886.247.946.564.320.00-3.3836.770.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00-0.02
Other Financing Activities Uses0.000.000.000.000.000.000.000.00-0.02
Cash from Financing Activities53.7086.247.946.564.320.00-3.3836.77-0.02
Net Change in Cash-0.720.810.65-0.00-11.06-6.15-13.3927.87-5.55
Free Cash Flow-17.93-13.11-8.85-8.57-11.63-9.42-7.34-6.67-5.53
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments68.3873.5178.5980.2132.7330.44
Short Term Receivables0.180.100.240.000.000.00
Inventories2.912.260.580.000.000.00
Other Current Assets0.710.660.400.570.160.22
Total Current Assets72.1776.5379.8280.7832.8930.66
Net Property, Plant & Equipment1.121.060.930.970.240.24
Total Investments and Advances0.060.060.060.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.19---
Other Assets0.010.420.740.000.000.00
Total Assets73.3678.0781.7381.7633.1330.89
Short Term Debt Incl. Current Port. of LT Debt0.330.320.300.300.100.09
Accounts Payable0.871.080.510.510.500.19
Other Current Liabilities2.691.982.612.132.121.62
Total Current Liabilities3.893.393.422.932.731.89
Long Term Debt0.550.570.570.600.050.05
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.19---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.443.964.183.542.771.94
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity68.9374.1177.5578.2230.3628.95
Total Shareholders Equity68.9374.1177.5578.2230.3628.95
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity68.9374.1177.5578.2230.3628.95
Total Liabilities & Stockholders Equity73.3678.0781.7381.7633.1330.89
Book Value Per Share1.031.101.151.190.800.83
Tangible Book Value Per Share1.031.101.151.190.800.83
Full-Time Employees--43---
Price to Book Ratio1.022.091.683.813.028.30
Return on Assets-30.68-26.09-29.95-30.06-62.65-61.02
Return on Equity-32.91-27.58-32.42-31.87-69.80-66.48
Return on Invested Capital-8.10-4.92-4.43-4.54-11.51-8.97
Quick Ratio17.8221.9323.1627.5312.0616.19
Current Ratio18.5622.5923.3327.5312.0616.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.63-3.67-3.46-3.58-3.50-2.60
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)0.440.000.520.170.120.26
Funds from Operations-5.17-3.66-2.94-3.40-3.37-2.33
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.18-1.39-0.82-0.440.80-0.54
Cash from Operating Activities-4.99-5.05-3.76-3.84-2.57-2.87
Capital Expenditures-0.14-0.11-0.03-0.01-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments4.626.06-1.51-44.70-1.30-24.82
Purchase of Investments-0.63-0.44-3.01-48.00-3.80-28.12
Sale Or Maturity of Investments5.256.501.503.302.503.30
Other Uses-0.01-0.950.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities4.475.00-1.53-44.71-1.31-24.83
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.020.002.5151.184.7527.81
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.020.002.5151.184.7527.81
Proceedsfrom Stock Options0.000.002.5151.174.7527.81
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.020.002.5151.184.7527.81
Net Change in Cash-0.50-0.06-2.792.620.870.10
Free Cash Flow-5.13-5.16-3.78-3.85-2.58-2.89

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.36%6.3M61.0M712.19K
2026-10-159.81%6.0M61.0M667.16K
2026-09-3010.88%6.6M61.0M628.26K
2026-09-1511.59%7.1M61.0M677.61K
2026-08-3111.85%7.2M61.0M775.01K
2026-08-1411.77%7.2M61.0M1.00M
2026-07-3112.11%7.4M61.0M1.18M
2026-07-1512.27%7.5M61.0M1.35M
2026-06-3012.04%7.3M61.0M1.50M
2026-06-1512.27%7.5M61.0M1.60M
2026-05-2912.52%7.6M61.0M1.78M
2026-05-1512.58%7.7M61.0M1.82M
2026-04-3012.63%7.7M61.0M2.12M
2026-04-1514.03%8.6M61.0M2.11M
2026-03-3113.21%8.1M61.0M1.99M
2026-03-1312.45%7.6M61.0M2.00M
2026-02-2712.35%7.5M61.0M2.18M
2026-02-1312.06%7.4M61.0M2.27M
2026-01-309.90%6.0M61.0M1.96M
2026-01-1510.19%6.8M67.0M2.17M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.044.15832.000.000.172-0.0100.000
call5.000.000.050.006.0140.000.000.138-0.0120.000
call7.500.001.000.007.1310.000.000.123-0.0140.000
put2.501.101.850.0010.4370.000.00-0.828-0.0100.000
put5.003.404.400.0013.4150.000.00-0.865-0.0120.000
put7.505.906.900.0014.5950.000.00-0.876-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-03ARSAnnual report to security holders. 2025-12-31SEC
2026-11-03DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-11-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-03SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-208-KCurrent report2026-10-14SEC
2026-10-068-KCurrent report2026-10-06SEC
2026-09-288-KCurrent report2026-09-25SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-06SEC
2026-07-218-KCurrent report2026-07-21SEC
2026-07-078-KCurrent report2026-07-07SEC
2026-06-308-KCurrent report2026-06-30SEC
2026-06-258-KCurrent report2026-06-25SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-168-KCurrent report2026-06-16SEC
2026-06-098-KCurrent report2026-06-09SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-268-KCurrent report2026-05-26SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-04-308-KCurrent report2026-04-30SEC
2026-04-228-KCurrent report2026-04-22SEC
2026-04-148-KCurrent report2026-04-14SEC
2026-04-138-KCurrent report2026-04-13SEC
2026-04-10424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.33%
Mitsubishi UFJ Asset Management Co., Ltd.1.98%
BlackRock, Inc.1.34%
UBS Group AG1.26%
GEODE CAPITAL MANAGEMENT, LLC1.16%
DnB Asset Management AS1.01%
STIFEL FINANCIAL CORP0.88%
MARSHALL WACE, LLP0.81%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.78%
VANGUARD FIDUCIARY TRUST CO0.64%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.14%
VANGUARD EXTENDED MARKET INDEX FUND1.10%
Fidelity Extended Market Index Fund0.54%
AlphaCentric Robotics and Automation Fund0.37%
iShares Micro-Cap ETF0.34%
Fidelity Total Market Index Fund0.17%
Fidelity Series Total Market Index Fund0.15%
Invesco NASDAQ Future Gen 200 ETF0.08%
Schwab Total Stock Market Index Fund0.07%
Ultra-Small Company Fund0.07%

OakChart. MBOT. Cached 15 minutes.

Some panels did not load: insider.